Editas Medicine share price today

(EDIT)

Editas Medicine share price is $1.16 & ₹100.36 as on 14 Jan 2025, 2.30 'hrs' IST

$1.16

▲

-0.1

(-7.94%)

Market is closed - opens 8 PM, 14 Jan 2025

View live Editas Medicine share price in Dollar and Rupees. Guide to invest in Editas Medicine stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Editas Medicine, along with analyst recommendations, forecasts, and comprehensive financials.

Editas Medicine share price movements

Today's Low: $1.16
Today's High: $1.23
$1.16
0.0%
Downside
Day's Volatility :5.69%
Upside
5.69%
52 Weeks Low: $1.16
52 Weeks High: $11.58
$1.16
0.0%
Downside
52 Weeks Volatility :89.98%
Upside
89.98%

Editas Medicine Returns

Period	Editas Medicine Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-62.5%	-9.3%	0.0%
6 Months	-78.86%	-5.8%	0.0%
1 Year	-85.73%	-0.6%	0.0%
3 Years	-93.69%	4.0%	-18.1%

Editas Medicine Key Statistics

in dollars & INR

Previous Close	$1.26
Open	$1.24
Today's High	$1.23
Today's Low	$1.16
Market Capitalization	$104.0M
Today's Volume	$2.5M
52 Week High	$11.58
52 Week Low	$1.16
Revenue TTM	$61.8M
EBITDA	$-222.6M
Earnings Per Share (EPS)	$-2.54
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-78.56%

How to invest in Editas Medicine from India?

It is very easy for Indian residents to invest directly in Editas Medicine from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Editas Medicine stock in both Indian Rupees (INR) and US Dollars (USD). Search for Editas Medicine or EDIT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Editas Medicine or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Editas Medicine shares which would translate to 0.746 fractional shares of Editas Medicine as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Editas Medicine, in just a few clicks!

Returns in Editas Medicine for Indian investors in Rupees

Investment Value

₹1,00,000

Editas Medicine investment value today

Current value as on today

₹17,518

Returns

₹82,482

(-82.48%)

Returns from Editas Medicine Stock

₹86,863 (-86.86%)

Dollar Returns

₹4,381 (+4.38%)

Indian investors sentiment towards Editas Medicine

45%

Period: Oct 15, 2024 to Jan 13, 2025. Change in 30 Days versus previous period

Search volume for Editas Medicine on INDmoney from India has grown in the last 30 days as on Jan 14, 2025. 45% more investors are searching Editas Medicine in the last 30 days versus the previous period.

Global Institutional Holdings in Editas Medicine

BlackRock Inc
9.72%
Vanguard Group Inc
8.09%
Deep Track Capital, LP
5.94%
Millennium Management LLC
4.06%
State Street Corp
2.98%
Dimensional Fund Advisors, Inc.
2.75%

Analyst Recommendation on Editas Medicine

Buy

54%Buy

41%Hold

4%Sell

Based on 24 Wall street analysts offering stock ratings for Editas Medicine(by analysts ranked 0 to 5 stars)

Based on 24 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Editas Medicine

What analysts predicted

Upside of 223.28%

Target:

$3.75

Current:

$1.16

Insights on Editas Medicine

Price Movement
In the last 3 months, EDIT stock has moved down by -60.5%
Decreasing Revenue
Revenue is down for the last 4 quarters, 60.04M → 61.0K (in $), with an average decrease of 80.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -67.60M → -62.14M (in $), with an average increase of 8.8% per quarter
EDIT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.1% return, outperforming this stock by 109.2%
EDIT vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 60.8% return, outperforming this stock by 155.0%
Price to Sales
ForEDIT every $1 of sales, investors are willing to pay $1.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.4 for every $1 of sales.

Editas Medicine Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$31.9M	↑ 132.64%
Net Income	$-110.0M	↓ 8.62%
Net Profit Margin	-344.28%	↑ 532.21%

	FY19	Y/Y Change
Revenue	$20.5M	↓ 35.71%
Net Income	$-123.5M	↑ 12.29%
Net Profit Margin	-601.36%	↓ 257.08%

	FY20	Y/Y Change
Revenue	$90.7M	↑ 341.93%
Net Income	$-109.4M	↓ 11.38%
Net Profit Margin	-120.59%	↑ 480.77%

	FY21	Y/Y Change
Revenue	$25.5M	↓ 71.85%
Net Income	$-185.1M	↑ 69.18%
Net Profit Margin	-724.66%	↓ 604.07%

	FY22	Y/Y Change
Revenue	$19.7M	↓ 22.83%
Net Income	$-204.4M	↑ 10.4%
Net Profit Margin	-1.0K%	↓ 312.03%

	FY23	Y/Y Change
Revenue	$78.1M	↑ 296.32%
Net Income	$-153.2M	↓ 25.02%
Net Profit Margin	-196.13%	↑ 840.56%

	Q2 FY23	Q/Q Change
Revenue	$2.9M	↓ 70.69%
Net Income	$-40.3M	↓ 11.58%
Net Profit Margin	-1.4K%	↓ 933.01%

	Q3 FY23	Q/Q Change
Revenue	$5.3M	↑ 84.83%
Net Income	$-45.0M	↑ 11.74%
Net Profit Margin	-843.68%	↑ 551.89%

	Q4 FY23	Q/Q Change
Revenue	$60.0M	↑ 1025.36%
Net Income	$-18.9M	↓ 58.08%
Net Profit Margin	-31.43%	↑ 812.25%

	Q1 FY24	Q/Q Change
Revenue	$1.1M	↓ 98.11%
Net Income	$-62.0M	↑ 228.23%
Net Profit Margin	-5.5K%	↓ 5426.72%

	Q2 FY24	Q/Q Change
Revenue	$513.0K	↓ 54.8%
Net Income	$-67.6M	↑ 9.13%
Net Profit Margin	-13.2K%	↓ 7720.6%

	Q3 FY24	Q/Q Change
Revenue	$61.0K	↓ 88.11%
Net Income	$-62.1M	↓ 8.08%
Net Profit Margin	-101.9K%	↓ 88691.74%

	FY18	Y/Y Change
Profit	$31.9M	↑ 132.64%

	FY19	Y/Y Change
Profit	$-76.4M	↓ 339.12%

	FY20	Y/Y Change
Profit	$90.7M	↓ 218.81%

	FY21	Y/Y Change
Profit	$25.5M	↓ 71.85%

	FY22	Y/Y Change
Profit	$19.7M	↓ 22.83%

	FY23	Y/Y Change
Profit	$-99.5M	↓ 604.91%

	Q2 FY23	Q/Q Change
Profit	$1.3M	↓ 83.78%

	Q3 FY23	Q/Q Change
Profit	$3.8M	↑ 183.74%

	Q4 FY23	Q/Q Change
Profit	$58.6M	↑ 1432.78%

	Q1 FY24	Q/Q Change
Profit	$-274.0K	↓ 100.47%

	Q2 FY24	Q/Q Change
Profit	$-907.0K	↑ 231.02%

	Q3 FY24	Q/Q Change
Profit	$-1.5M	↑ 69.57%

	FY18	Y/Y Change
Operating Cash Flow	$-45.7M	↑ 385.37%
Investing Cash Flow	$-53.1M	↓ 71.12%
Financing Cash Flow	$86.9M	↓ 43.74%

	FY19	Y/Y Change
Operating Cash Flow	$-40.7M	↓ 11.02%
Investing Cash Flow	$12.3M	↓ 123.08%
Financing Cash Flow	$131.8M	↑ 51.63%

	FY20	Y/Y Change
Operating Cash Flow	$-179.8M	↑ 342.21%
Investing Cash Flow	$-140.5M	↓ 1246.93%
Financing Cash Flow	$224.1M	↑ 70.02%

	FY21	Y/Y Change
Operating Cash Flow	$-163.8M	↓ 8.92%
Investing Cash Flow	$-54.5M	↓ 61.24%
Financing Cash Flow	$282.1M	↑ 25.87%

	FY22	Y/Y Change
Operating Cash Flow	$-177.3M	↑ 8.27%
Investing Cash Flow	$114.1M	↓ 309.43%
Financing Cash Flow	$1.3M	↓ 99.54%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-38.7M	↑ 8.23%
Investing Cash Flow	$13.0M	↓ 44.2%
Financing Cash Flow	$117.5M	↑ 3008.3%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-35.5M	↓ 8.4%
Investing Cash Flow	$-102.8M	↓ 892.02%
Financing Cash Flow	$0.0	↓ 100.0%

Editas Medicine Technicals Summary

Sell

Neutral

Buy

Editas Medicine is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Editas Medicine Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Editas Medicine Inc.	-14.86%	-78.86%	-85.73%	-93.69%	-96.06%
Regeneron Pharmaceuticals, Inc.	-3.86%	-36.36%	-25.65%	14.01%	80.74%
Biontech Se	7.56%	41.5%	23.38%	-27.41%	280.93%
Alnylam Pharmaceuticals, Inc.	-2.46%	-4.74%	26.93%	70.97%	99.41%
Vertex Pharmaceuticals Incorporated	-12.5%	-16.24%	-6.38%	77.24%	73.91%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Editas Medicine Inc.	NA	NA	0.0	-2.69	-0.79	-0.34	NA	2.13
Regeneron Pharmaceuticals, Inc.	17.24	17.24	1.03	44.96	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.2	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.07	0.49	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Editas Medicine Inc.	Buy	$104.0M	-96.06%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$76.6B	80.74%	17.24	33.61%
Biontech Se	Buy	$29.5B	280.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.7B	99.41%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$105.5B	73.91%	32.84	-4.51%

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Organization	Editas Medicine
Employees	265
CEO	Dr. Gilmore O'Neill M.D.
Industry	Health Technology

Management People of Editas Medicine

Name	Title
Dr. Gilmore O'Neill M.D.	President, CEO & Director
Mr. Erick J. Lucera C.F.A., CPA	CFO & Executive VP
Dr. Linda C. Burkly Ph.D.	Executive VP & Chief Scientific Officer
Dr. Baisong Mei M.D., Ph.D.	Executive VP & Chief Medical Officer
Dr. Feng Zhang Ph.D.	Co-Founder & Scientific Advisory Board Member
Dr. George McDonald Church Ph.D.	Co-Founder & Scientific Advisory Board Member
Mr. Gregory Whitehead	Executive VP and Chief Technical & Quality Officer
Cristi Barnett	Corporate Communications & Investor Relations
Ms. Charlene Stern J.D., Ph.D.	Executive VP & General Counsel
Ms. Linea Aspesi	Executive VP & Chief People Officer

Important FAQs about investing in Editas Medicine from India :

What is Editas Medicine share price today?

Editas Medicine share price today stands at $1.16, Open: $1.24 ; Previous Close: $1.26 ; High: $1.23 ; Low: $1.16 ; 52 Week High: $11.58 ; 52 Week Low: $1.16. The stock opens at $1.24, after a previous close of $1.26. The stock reached a daily high of $1.23 and a low of $1.16, with a 52-week high of $11.58 and a 52-week low of $1.16.

Can Indians buy Editas Medicine shares?

Yes, Indians can invest in the Editas Medicine (EDIT) from India.

With INDmoney, you can buy Editas Medicine at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Editas Medicine at zero transaction cost.

How can I buy Editas Medicine shares from India?

It is very easy to buy Editas Medicine from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Editas Medicine be purchased?

Yes, you can buy fractional shares of Editas Medicine with INDmoney app.

What are the documents required to start investing in Editas Medicine stocks?

To start investing in Editas Medicine, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.